Genetic-Driven Care:
Translating DNA into a battle plan.
A list of mutations is not a treatment plan. We turn your data into action.
Standard testing labs operate on a simple model: they draw blood or tissue, run it through a machine, and send you a 40-page genomic PDF filled with complex jargon, endless tables, and vague probabilities. They drop this heavy document into your lap, leaving you and your already-overworked doctor wondering, "What do we actually do with this?" Genomic data is entirely useless—and often overwhelming—if it isn't translated into a concrete, sequential clinical strategy that you can actually access in India today.
Crucially, we bundle this intelligence with 3 months of our complete Blueprint Care subscription. This means you receive absolutely everything included in our standard monthly care pathways—the weekly check-ins, the PAP financial navigation, and the dedicated coordinator—to help you actually execute the plan your DNA demands.
From Data to War Plan
Raw mutation list → Clinical strategy → Execution with dedicated support
Is Genetic‑Driven Care
Right for You?
Advanced cancer requires advanced intelligence.
Standard protocols are built for the "average" patient, but your cancer is entirely unique. This pathway is built for patients and families who cannot rely on guesswork, who refuse to wait and see if a standard drug fails, and who need the absolute deepest understanding of their disease to find hidden treatment options.
This pathway is for you if:
- You have already spent lakhs on a massive genomic test from another lab (like MedGenome, FoundationOne, or Guardant) but received a confusing, highly technical report that nobody has fully explained how to act upon.
- Standard "Line 1" treatments (like traditional platinum-based chemotherapy) have stopped working, the cancer is progressing, and you need to uncover entirely new targeted therapies, immunotherapies, or early-phase clinical trials.
- You have been diagnosed with an advanced (Stage 3/4), rare, or heavily refractory cancer and need to know every single biological vulnerability your tumor currently has.
- You want to avoid the severe, toxic side effects of chemotherapy drugs that, biologically, will not work for your specific tumor due to underlying resistance mutations.
- You need to definitively know your tumor's MSI (Microsatellite Instability) or TMB (Tumor Mutational Burden) status to see if you are biologically eligible for advanced Immunotherapy options.
Choose Your Pathway
- Signature Targeted (16-Gene)₹1,50,000Fast blood draw – genes with drugs approved & accessible in India today. For urgent decisions.
- Signature Baseline (118-Gene)₹2,50,000Complete molecular fingerprint from blood – vital baseline for future monitoring.
- Signature Tissue Full (177-Gene + MSI + TMB)₹3,00,000Deepest read from existing biopsy block. No re-biopsy needed.
- Signature Complete CGP (523-Gene)₹7,00,000Ultimate comprehensive blood draw for Stage 4, multi-line, or refractory cancers.
- Signature AML/ALL (7-Day TAT)₹1,50,000Critical 7-day turnaround for leukemia – because days matter.
The Onkommon Intelligence Engine
1. Therapies with Resistance
Preventing Toxic Mistakes
Standard care often involves trying a drug to see if it works. We use your genetics to identify drugs that will not work before you even take them. For example, if your tumor carries a specific TP53 mutation, it may be biologically resistant to platinum-based chemotherapy. We flag this resistance immediately so you do not suffer severe toxicities from a drug that has no chance of curing you.
2. Off-Label & Cross-Tumor Approvals
Unlocking Hidden Doors
Sometimes the precise drug that will save your life was approved for a completely different cancer. If you have Thyroid cancer but carry a PTEN mutation common in Breast cancer, standard reports might miss it. We map the exact clinical evidence to justify using that targeted therapy off-label, giving your doctor the evidence they need.
3. Biosimilar Mapping
Radical Cost Reduction
Biologic drugs can cost lakhs per month. Our report automatically maps expensive branded drugs to CDSCO-approved biosimilars available in India. You receive the exact same clinical efficacy at a fraction of the cost, making treatment financially sustainable.
4. Synergistic Combinations
The Multi-Pronged Attack
Cancer is adaptable. We don't just look for single drug targets; we identify powerful combinations that attack the tumor from multiple angles simultaneously, helping overcome natural resistance mechanisms before they form.
5. Sequencing Considerations
Playing the Right Cards, in Order
Cancer treatment is a chess match. If your tumor has multiple driver mutations, we outline exactly what order your doctor should use available drugs – when to use targeted therapies first, and when to hold back immunotherapies based on your TMB and MSI status.
6. Clonal Architecture & Dominance
Target the Trunk, Not the Branches
We map the "Clonal Architecture" of your tumor to distinguish between the primary driver (the trunk causing main growth) and secondary mutations (the branches). This ensures your oncologist strikes at the root cause, not minor branches.
7. Pharmacogenomics Overlay
Metabolism Profiling
A drug only works if your body can process it. Our report analyzes how your liver and enzymes will metabolize recommended therapies – helping your doctor adjust dosages perfectly to prevent severe toxicity or treatment failure.
Advanced Computational Infrastructure
1. AI-Powered VUS Annotation
In standard testing, many mutations return as "VUS" (Variant of Uncertain Significance) – the lab simply doesn't know if the mutation is harmful. We refuse ambiguity. Our machine learning algorithms deeply analyze VUS findings against massive datasets, identifying hidden oncogenic targets that standard labs entirely miss.
2. Advanced Genomic Interpretation
We don't hand you a confusing list of mutated genes. We transform raw complex genomic data into highly actionable clinical insights – comparing your tumor against global libraries, literature, and trial outcomes to pinpoint exact oncogenic drivers and drug response biomarkers.
3. Real-Time Cohort Statistics
Your cancer cannot be evaluated in isolation. Our platform generates real‑time visualizations from vast patient data, including the specialized KCCIRC Northeast India variant cohort. This prevents misclassification of variants common in Indian populations and supports your oncologist with localized, statistically backed evidence.
4. International vMTB + In-Person KCCIRC Tumour Board
The Virtual International Board (vMTB): Powered by CGI Teams, our advanced vMTB module securely shares your molecular data with an international, multidisciplinary panel of world‑class oncology experts. They collaboratively debate, analyze, and build a strategic war plan for your complex case.
The In-Person KCCIRC Board Meeting: Every Genetic‑Driven pathway includes one dedicated, in‑person Tumour Board consultation at our state‑of‑the‑art KCCIRC clinics in Delhi or Sikkim. You and your family will sit directly with our local clinical experts to review the international board's findings, translating global strategy into a precise, actionable, and accessible roadmap for your treatment in India.
The 3‑Month Blueprint Care Bundle
Your Dedicated Coordinator & In‑Person Sessions
You are assigned a named Clinical Coordinator who checks in with you weekly via phone or WhatsApp. You also have the option for up to two in‑person meetings per month at our KCCIRC clinics.
The Financial Shield (PAP & Charity Management)
We take on the grueling administrative paperwork required to apply for Patient Assistance Programs (PAPs) and pharmaceutical charity schemes, fighting to radically lower your out‑of‑pocket costs for the targeted therapies identified in your report.
Active Trial Matching & Enrollment
If your genomic report identifies you as a match for an active clinical trial running in India (or internationally), we actively coordinate with the trial investigators and your doctor to push for your immediate enrollment.
Full Logistical Coordination & Toxicity Tracking
We manage your hospital appointments, brief your family caregivers, track your day‑to‑day side effects, and cross‑reference your cancer medications against your daily medications to prevent dangerous interactions.
How It Works
The Process
Frequently Asked Questions
Absolutely not. If your current report is recent and comprehensive, you are the perfect candidate for our Blueprint Decipher pathway. We will take your existing PDF report, run it through our advanced intelligence engine, and map the findings directly to the Indian healthcare reality. We believe in maximizing the data you already have and never push unnecessary re‑testing.
Our vMTB (Virtual Molecular Tumour Board) allows our team to consult securely with international experts on your specific molecular data. Following this global review, you are entitled to one in‑person session at KCCIRC in Delhi or Sikkim. During this face‑to‑face meeting, our local clinical experts will sit with you, explain the international board's findings, and plan your precise next steps for treatment in India.
Yes. There are no compromises. The 3 months of Blueprint Care bundled with your genetic pathway includes the exact same weekly check‑ins, PAP financial management, trial hunting, and in‑person meeting options as our standalone monthly subscription.
A VUS stands for "Variant of Uncertain Significance." It means standard testing labs cannot tell if the mutation is harmful or benign, so they ignore it. We refuse to ignore data. We use our Automatic Learning Platform and machine learning to deeply annotate these findings against massive databases, often discovering that a VUS is actually a highly targetable mutation that standard labs simply missed.
Many targeted therapies and immunotherapies are incredibly expensive, branded biologic drugs. A "biosimilar" is a highly similar, clinically equivalent version of that drug made by a different manufacturer, often available at a significantly lower cost. Our reports automatically map the expensive branded drugs to CDSCO‑approved biosimilars available right here in India, drastically reducing your financial burden without sacrificing efficacy.
No. Your Onkommon Care Coordinator is an expert clinical strategist and logistical navigator. They will arm your current treating medical oncologist with this incredibly detailed, evidence‑based war plan. Your treating oncologist remains the licensed physician who officially prescribes the medication and oversees your medical care.